Evidence map›Paper›PMID 26754777›Full record

ReviewJournal of clinical neurology (Seoul, Korea)2016

The Diagnosis and Treatment of Autoimmune Encephalitis.

Eric Lancaster

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical neurology (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 5 pooled it
35.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 5 syntheses or guidelines pooled it, 432 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2023
    Pooled it
  4. Pooled it
  5. [18F]FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  6. Article
  7. Article
  8. Article
  9. Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Managing paraneoplastic GABABMC neurology · 2025
    Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Eric LancasterDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA. eric.lancaster@uphs.upenn.edu.
University of Pennsylvania · US

Funding

Mechanisms of Caspr2 antibodiesK08NS075142 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LANCASTER, ERIC · 2012 to 2016
$948k
NINDS NIH HHS K08 NS075142
6 · The paper itself

Abstract

Autoimmune encephalitis causes subacute deficits of memory and cognition, often followed by suppressed level of consciousness or coma. A careful history and examination may show early clues to particular autoimmune causes, such as neuromyotonia, hyperekplexia, psychosis, dystonia, or the presence of particular tumors. Ancillary testing with MRI and EEG may be helpful for excluding other causes, managing seizures, and, rarely, for identifying characteristic findings. Appropriate autoantibody testing can confirm specific diagnoses, although this is often done in parallel with exclusion of infectious and other causes. Autoimmune encephalitis may be divided into several groups of diseases: those with pathogenic antibodies to cell surface proteins, those with antibodies to intracellular synaptic proteins, T-cell diseases associated with antibodies to intracellular antigens, and those associated with other autoimmune disorders. Many forms of autoimmune encephalitis are paraneoplastic, and each of these conveys a distinct risk profile for various tumors. Tumor screening and, if necessary, treatment is essential to proper management. Most forms of autoimmune encephalitis respond to immune therapies, although powerful immune suppression for weeks or months may be needed in difficult cases. Autoimmune encephalitis may relapse, so follow-up care is important.

Indexed as

antibodyanti-NMDAR encephalitisautoimmuneencephalitisparaneoplastic

Identifiers

PMID26754777
PMCPMC4712273
OpenAlexW2225011328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.